Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Solid Tumours

In brief

To determined what dose of topotecan can be safely given with daily pazopanib.

Key facts

Study ID

NCT00732420

Run by

GlaxoSmithKline

People needed

68

Starts

2008-09-24

Expected to finish

2013-06-12

Last updated by the study team

2017-11-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C)
• received an investigational drug within 30 days or 5 half-lives (whichever is longer).
• received prior treatment with pazopanib/investigational anti-angiogenic compounds.
• presence of uncontrolled infection.
• pregnant or lactating.
• poorly controlled hypertension (SBP of ? 140 mmHg, or DBP of ? 90 mmHg.
• Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system.-
• arterial thrombi, myocardial infarction, admission for unstable angina, uncontrolled or symptomatic arrhythmia, cardiac angioplasty, or stenting within the last 6 months.
• any unresolved bowel obstruction or diarrhea ? Grade 1.
• received an allogeneic bone marrow transplant.
• known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or topotecan.
• any serious and/or unstable pre-existing medical, psychiatric, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance with the study.
• psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
• clinical history, current alcohol or illicit drug use which, in the judgment of the investigator, would interfere with the subject's ability to comply with the dosing schedule and protocol-specified evaluations.

Where it is running

• GSK Investigational Site — Philadelphia, Pennsylvania, United States
• GSK Investigational Site — Amsterdam, Netherlands
• GSK Investigational Site — Utrecht, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.